Sean S Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9007402/publications.pdf

Version: 2024-02-01

218677 223800 2,633 95 26 46 h-index citations g-index papers 96 96 96 4298 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. Clinical Genitourinary Cancer, 2022, 20, 107-113.	1.9	3
2	Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases. JAMA Oncology, 2022, 8, 412.	7.1	21
3	Intensity Modulated Proton Therapy for Bilateral Breast or Chest Wall and Comprehensive Nodal Irradiation for Synchronous Bilateral Breast Cancer: Initial Clinical Experience and Dosimetric Comparison. Advances in Radiation Oncology, 2022, 7, 100901.	1.2	3
4	Development and Internal Validation of a Recursive Partitioning Analysis–Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation Therapy. Practical Radiation Oncology, 2022, 12, e269-e277.	2.1	9
5	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade. Advances in Radiation Oncology, 2022, 7, 100931.	1.2	4
6	NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunology Research, 2022, 10, 162-181.	3.4	26
7	A Dosimetric Comparison of Lattice, Brass, and Proton Grid Therapy Treatment Plans. Practical Radiation Oncology, 2022, 12, e442-e452.	2.1	8
8	Proton therapy for the treatment of inflammatory breast cancer. Radiotherapy and Oncology, 2022, 171, 77-83.	0.6	4
9	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. BMJ Open, 2022, 12, e050112.	1.9	6
10	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	5.4	52
11	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 387-395.	0.8	19
12	VMAT Grid Therapy: A Widely Applicable Planning Approach. Practical Radiation Oncology, 2021, 11, e339-e347.	2.1	25
13	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clinical and Translational Immunology, 2021, 10, e1267.	3.8	4
14	Reirradiation for Locoregional Recurrent Breast Cancer. Advances in Radiation Oncology, 2021, 6, 100640.	1.2	20
15	Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. Radiotherapy and Oncology, 2021, 158, 246-252.	0.6	9
16	Functional avoidanceâ€based intensity modulated proton therapy with 4DCT derived ventilation imaging for lung cancer. Journal of Applied Clinical Medical Physics, 2021, 22, 276-285.	1.9	1
17	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. JAMA Oncology, 2021, 7, 845.	7.1	56
18	Musculoskeletal Oncologic Interventions: Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2021, 32, 1089.e1-1089.e9.	0.5	9

#	Article	IF	CITATIONS
19	Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e54-e62.	0.8	7
20	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6376-6383.	7.0	21
21	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nuclear Medicine and Biology, 2021, 100-101, 4-11.	0.6	6
22	Hypofractionated Irradiation and Immune Modulation Therapies: Let's Work Together!. International Journal of Radiation Oncology Biology Physics, 2021, 111, 589-591.	0.8	0
23	Incorporation of Biologic Response Variance Modeling Into the Clinic: Limiting Risk of Brachial Plexopathy and Other Late Effects of Breast Cancer Proton Beam Therapy. Practical Radiation Oncology, 2020, 10, e71-e81.	2.1	15
24	Linear accelerator-based single-fraction stereotactic body radiotherapy for symptomatic vertebral body hemangiomas: The Mayo Clinic experience. Journal of Clinical Neuroscience, 2020, 80, 74-78.	1.5	7
25	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. , 2020, 8, e001113.		32
26	Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiotherapy and Oncology, 2020, 146, 29-36.	0.6	20
27	Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapyâ€Related Bone Loss. Journal of Bone and Mineral Research, 2020, 35, 1119-1131.	2.8	74
28	Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. Frontiers in Oncology, 2020, 10, 392.	2.8	0
29	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 561083.	4.8	12
30	In Reply to Hannoun-Levi and Hannoun. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1177-1179.	0.8	0
31	11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities. Advances in Radiation Oncology, 2019, 4, 659-667.	1.2	12
32	Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: Initial report of reconstruction outcomes and predictors of complications. Radiotherapy and Oncology, 2019, 140, 76-83.	0.6	34
33	Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC. Advances in Radiation Oncology, 2019, 4, 422-428.	1.2	24
34	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Advances in Radiation Oncology, 2019, 4, 314-322.	1,2	9
35	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Advances in Radiation Oncology, 2019, 4, 79-89.	1.2	2
36	Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. International Journal of Radiation Oncology Biology Physics, 2019, 104, 75-82.	0.8	27

#	Article	IF	CITATIONS
37	3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. Radiation Oncology, 2019, 14, 211.	2.7	23
38	Potential role of senescence in radiation-induced damage of the aged skeleton. Bone, 2019, 120, 423-431.	2.9	31
39	Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 229-240.	0.8	24
40	Carbon Fiducial Image Guidance Increases the Accuracy of Lumpectomy Cavity Localization in Radiation Therapy for Breast Cancer. Practical Radiation Oncology, 2019, 9, e14-e21.	2.1	3
41	Phantom Verification of AAA and Acuros Dose Calculations for Lung Cancer: Do Tumor Size and Regression Matter?. Practical Radiation Oncology, 2019, 9, 29-37.	2.1	13
42	Contraction of T cell richness in lung cancer brain metastases. Scientific Reports, 2018, 8, 2171.	3.3	74
43	Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. Breast Cancer Research and Treatment, 2018, 169, 189-196.	2.5	8
44	Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non–Small Cell Lung Cancer: The Mayo Clinic Experience. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 40-48.	2.4	19
45	Gemcitabine-Induced Radiation Recall Myositis: Case Report and Review of the Literature. Case Reports in Oncology, 2018, 11, 168-178.	0.7	13
46	Durable response of early-stage breast cancer to bilateral definitive SBRT in a medically inoperable patient. Practical Radiation Oncology, 2018, 8, 361-365.	2.1	5
47	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using ¹¹ C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. Journal of Urology, 2018, 199, 726-733.	0.4	13
48	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology, 2018, 9, 1739.	4.8	174
49	CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCl Insight, 2018, 3, .	5.0	106
50	Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports. Practical Radiation Oncology, 2017, 7, e243-e252.	2.1	34
51	Risk of Delayed Lymph Node Metastasis in Clinically NO Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 068-074.	0.8	21
52	Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT). Breast Cancer Research and Treatment, 2017, 164, 237-244.	2.5	26
53	Sternum First, Perhaps Pelvis Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 496.	0.8	0
54	18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Advances in Radiation Oncology, 2017, 2, 204-210.	1.2	10

#	Article	IF	Citations
55	Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) nonâ \in ⁴ small cell lung cancer. Advances in Radiation Oncology, 2017, 2, 12-18.	1.2	1
56	Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. Advances in Radiation Oncology, 2017, 2, 540-547.	1.2	27
57	Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clinical and Translational Radiation Oncology, 2017, 6, 25-30.	1.7	5
58	Patient safety is improved with an incident learning systemâ€"Clinical evidence in brachytherapy. Radiotherapy and Oncology, 2017, 125, 94-100.	0.6	12
59	FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. Practical Radiation Oncology, 2017, 7, e531-e541.	2.1	9
60	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.8	35
61	Delineation of Internal Mammary Nodal Target Volumes in Breast Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 762-769.	0.8	32
62	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	1.9	51
63	T cell Bim levels reflect responses to anti–PD-1 cancer therapy. JCI Insight, 2016, 1, .	5.0	68
64	Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. Brachytherapy, 2016, 15, 796-803.	0.5	6
65	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy, 2016, 8, 1351-1353.	2.0	6
66	A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3297-3303.	1.5	12
67	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Practical Radiation Oncology, 2016, 6, e117-e126.	2.1	26
68	Cadaveric verification of the Eclipse AAA algorithm for spine SBRT treatments with titanium hardware. Practical Radiation Oncology, 2016, 6, 131-141.	2.1	8
69	Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 696-702.	0.8	87
70	Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer. International Journal of Particle Therapy, 2016, 3, 407-413.	1.8	12
71	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunology Research, 2015, 3, 610-619.	3.4	327
72	Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung. Frontiers in Oncology, 2015, 4, 376.	2.8	6

#	Article	IF	CITATIONS
73	Definitive Management of Oligometastatic Melanoma in a Murine Model Using CombinedÂAblative Radiation Therapy andÂViralÂlmmunotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 577-587.	0.8	17
74	Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiation Oncology, 2015, 10, 43.	2.7	39
75	Delineation of Supraclavicular Target Volumes in Breast Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 642-649.	0.8	45
76	In Reply to Yang and Guo. International Journal of Radiation Oncology Biology Physics, 2015, 93, 723-724.	0.8	9
77	In Reply to Yartsev and Chen. Practical Radiation Oncology, 2015, 5, e555.	2.1	0
78	Synergy of cancer immunotherapy and radiotherapy. Aging, 2015, 7, 144-145.	3.1	9
79	Feasibility of Proton Transmission-Beam Stereotactic Ablative Radiotherapy versus Photon Stereotactic Ablative Radiotherapy for Lung Tumors: A Dosimetric and Feasibility Study. PLoS ONE, 2014, 9, e98621.	2.5	10
80	Analysis of automatic match results for cone-beam computed tomography localization of conventionally fractionated lung tumors. Practical Radiation Oncology, 2014, 4, 35-42.	2.1	6
81	Separating the dosimetric consequences of changing tumor anatomy from positional uncertainty for conventionally fractionated lung cancer patients. Practical Radiation Oncology, 2014, 4, 455-465.	2.1	8
82	Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Practical Radiation Oncology, 2014, 4, e143-e149.	2.1	62
83	External beam pulsed low dose radiotherapy using volumetric modulated arc therapy: Planning and delivery. Medical Physics, 2013, 40, 011704.	3.0	9
84	Pulsed Versus Conventional Radiation Therapy in Combination With Temozolomide in a Murine Orthotopic Model of Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2013, 86, 978-985.	0.8	24
85	Adaptive Image-Guided Radiotherapy (IGRT) Eliminates the Risk of Biochemical Failure Caused by the Bias of Rectal Distension in Prostate Cancer Treatment Planning: Clinical Evidence. International Journal of Radiation Oncology Biology Physics, 2012, 83, 947-952.	0.8	58
86	Oropharyngeal Cancer Biology and Treatment: Insights From Messenger RNA Sequence Analysis and Transoral Robotic Surgery. Mayo Clinic Proceedings, 2012, 87, 1132.	3.0	1
87	Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in Oncology, 2012, 2, 215.	2.8	107
88	Accelerated Partial Breast Irradiation for Pure Ductal Carcinoma in Situ. International Journal of Radiation Oncology Biology Physics, 2011, 81, 403-408.	0.8	31
89	Longitudinal Assessment of Quality of Life and Audiometric Test Outcomes in Vestibular Schwannoma Patients Treated With Gamma Knife Surgery. Otology and Neurotology, 2011, 32, 676-679.	1.3	21
90	Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. Magnetic Resonance Imaging, 2011, 29, 993-1001.	1.8	64

#	Article	IF	CITATION
91	MicroPET/CT Imaging of an Orthotopic Model of Human Glioblastoma Multiforme and Evaluation of Pulsed Low-Dose Irradiation. International Journal of Radiation Oncology Biology Physics, 2011, 80, 885-892.	0.8	35
92	Role of Pinin in neural crest, dorsal dermis, and axial skeleton development and its involvement in the regulation of Tcf/Lef activity in mice. Developmental Dynamics, 2007, 236, 2147-2158.	1.8	20
93	A Murine Model for Human Sepiapterin-Reductase Deficiency. American Journal of Human Genetics, 2006, 78, 575-587.	6.2	72
94	B-Cell Translocation Gene 2 (Btg2) Regulates Vertebral Patterning by Modulating Bone Morphogenetic Protein/Smad Signaling. Molecular and Cellular Biology, 2004, 24, 10256-10262.	2.3	67
95	Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist, 0, , .	3.7	10